Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
47 studies found for:    Icotinib OR BPI-2009H
Show Display Options
Rank Status Study
1 Recruiting Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease
Condition: NSCLC
Interventions: Drug: Icotinib of routine dose;   Drug: Icotinib of high dose
2 Active, not recruiting Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Icotinib with concurrent radiotherapy;   Drug: Chemoradiotherapy
3 Not yet recruiting Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations
Condition: Lung Cancer
Intervention: Drug: Endostar and icotinib
4 Not yet recruiting Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Icotinib;   Drug: Docetaxel
5 Recruiting Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Chemotherapy;   Drug: Icotinib+chemotherapy
6 Completed Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation
Conditions: Non-small Cell Lung Cancer;   Brain Metastases
Interventions: Drug: icotinib;   Radiation: Whole brain radiotherapy
7 Active, not recruiting Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
Conditions: EGFR Positive Non-small Cell Lung Cancer;   Adenocarcinoma
Interventions: Drug: Sequential Icotinib Plus Chemotherapy;   Drug: Icotinib
8 Completed Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer
Conditions: Lung Cancer;   Metastatic Cancer
Intervention: Drug: Icotinib
9 Not yet recruiting Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy
Condition: NSCLC
Intervention: Drug: Icotinib
10 Recruiting Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation
Condition: Non-small-cell Lung Cancer
Interventions: Drug: 1-year treatment with icotinib;   Drug: 2-year treatment with icotinib
11 Recruiting Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Icotinib of routine dose;   Drug: Icotinib of high dose
12 Active, not recruiting High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Routine dose icotinib;   Drug: Higher dose icotinib
13 Withdrawn Icotinib Hydrochloride in Treating Patients With Advanced Cancers
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: icotinib hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
14 Active, not recruiting Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC
Conditions: EGFR Positive Non-small Cell Lung Cancer;   Adenocarcinoma
Interventions: Drug: Sequential and maintenance icotinib;   Drug: Maintenance icotinib
15 Unknown  Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Icotinib;   Radiation: intensity-modulated radiotherapy;   Drug: Paclitaxel and Cisplatin;   Other: Quality of life;   Genetic: Epidermal growth factor receptor status
16 Recruiting Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer
Condition: Esophageal Cancer
Interventions: Drug: Icotinib;   Radiation: Thoracic radiotherapy
17 Recruiting Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
Condition: Non-small-cell Lung Cancer
Interventions: Drug: Icotinib;   Drug: Chemotherapy
18 Recruiting Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Icotinib;   Drug: Arsenic trioxide
19 Recruiting Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency
Condition: Non-small Cell Lung Cancer
Intervention: Drug: icotinib
20 Active, not recruiting A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: Icotinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years